SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

Escalating Middle East shipping and energy-infrastructure risks, especially around the Strait of Hormuz and Saudi Arabia, are fueling concern about oil-supply disruptions and drawing attention to USOs crude exposure. Traders are divided between betting that the geopolitical risk premium will sustain oils rise and expecting a sharp pullback if tensions ease or a deal emerges; some also warn the rally is overextended.

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, Peter Salanki, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeaves debt and refinancing risks are driving the discussion, amplified by HSBCs warning that borrowing costs and slower AI demand could weigh on growth. Traders are divided between fears that financing needs threaten the business and the view that strong AI demand and its contracted backlog can support it, with Goldmans more bullish stance adding to the debate.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJT is under pressure as traders connect the stocks slide to weakening confidence in Trump ahead of the midterms, alongside concerns about Truth Socials limited business scale, losses, and crypto exposure. Discussion is overwhelmingly bearish, though some traders see a possible short-term bounce and point to the pending TAE fusion deal as a potential diversification opportunity.

USA Rare Earth, Inc. is a domestic supplier of rare earth magnets and heavy rare earth elements. It develops a vertically integrated domestic supply chain for rare earth element magnet production, with a facility in Stillwater and mining rights to the Round Top heavy rare earth and critical minerals deposit in West Texas. The company was founded in May 2019 and is headquartered in Stillwater, OK.

USA Rare Earth Inc. - Ordinary Shares - Class A

USA Rare Earth Inc

A prolonged selloff has focused attention on USAR, with traders pointing to dilution concerns, heavy spending before production scales, and frustration with managements limited communication after the CEO transition. Bulls cite the companys strategic role in a U.S. rare-earth supply chain and government backing, while bears question execution and near-term economics.

Cerebras Systems, Inc. engages in the designing and provision of processors for artificial intelligence (AI) training and inference. Its products include inference, Wafer Scale Engine, AI supercomputers, AI model services, cloud, systems, and processors. The company was founded by Sean Lie, Andrew D. Feldman, Gary Lauterbach, Michael James, and Jean Philippe Fricker in 2015 and is headquartered in Sunnyvale, CA.

Cerebras Systems Inc - Ordinary Shares - Class A

Cerebras Systems Inc

Cerebras steep post-IPO selloff is drawing attention, with traders focused on recurring lockup expirations and insider share sales as potential sources of continued supply; a TD Cowen price-target cut and concerns about OpenAI dependence and competition from Nvidia add to the bearish debate. Some traders see the decline as an oversold buying opportunity, citing the companys AI-chip technology and demand prospects, while others expect more downside until selling pressure eases.

NuScale Power Corp. provides proprietary and innovative advanced small modular reactor (SMR) nuclear technology, with a mission to help power the global energy transition by delivering safe, scalable, and reliable carbon-free energy. Its products include VOYGR SMR Plants and Energy Exploration (E2) Centers. The company was founded by José N. Reyes in 2007 and is headquartered in Corvallis, OR.

NuScale Power Corporation - Ordinary Shares - Class A

NuScale Power Corp

Barclays downgrade of NuScale to Underweight, citing commercial execution risks and delays in firm customer commitmentsparticularly around the proposed TVA projecthas fueled the selloff. Traders are split between concerns that NuScale may struggle to convert its reactor technology into binding projects and bulls who see the decline as overdone given the long-term nuclear-power opportunity.

Salesforce, Inc. engages in the design and development of cloud-based enterprise software for customer relationship management. Its solutions include sales force automation, customer service and support, marketing automation, digital commerce, community management, collaboration, industry-specific solutions, and salesforce platform. The firm also provides guidance, support, training, and advisory services. The company was founded by Marc Russell Benioff and Parker Harris in 1999 and is headquartered in San Francisco, CA.

Salesforce Inc

Salesforces agreement to acquire customer-engagement platform Braze is drawing attention, with traders weighing the deals potential to strengthen Marketing Cloud and its AI strategy against concerns about the cost and pressure on CRM shares. Some also frame the deal as part of Salesforces broader push to expand its enterprise software offerings.

General Motors Co. engages in the designing, manufacturing, and selling of trucks, crossovers, cars, and automobile parts, and in providing software-enabled services and subscriptions. It operates through the following segments: GMNA, GMI, Cruise, and GM Financial. The company was founded by William C. Durant on September 16, 1908 and is headquartered in Detroit, MI.

General Motors Company

GMs quarterly earnings and revenue beat expectations, and the company authorized a large share buyback, but shares fell as traders focused on a narrowed full-year profit outlook that offered no improvement at its midpoint and weaker U.S. sales. Some see the buyback and cash flow as supportive, while others argue the cautious outlook outweighed the strong quarter.

RTX Corp. is an aerospace and defense company, which engages in the provision of aerospace and defense systems and services for commercial, military, and government customers. It operates through the following segments: Collins Aerospace Systems (Collins), Pratt and Whitney, Raytheon Intelligence and Space (RIS), and Raytheon Missiles and Defense (RMD). The Collins segment manufactures and sells aero structures, avionics, interiors, mechanical systems, mission systems, and power controls. The Pratt and Whitney segment includes the design and manufacture of aircraft engines and auxiliary power systems for commercial, military, and business aircraft. The RIS segment is involved in the development of sensors, training, and cyber and software solutions. The RMD segment offers end-to-end solutions to detect, track, and engage threats. The company was founded in 1922 and is headquartered in Arlington, VA.

RTX Corp

Raytheon Technologies Corporation

RTX is drawing attention after a broad quarterly earnings beat and a higher full-year outlook, backed by record backlog and demand across defense and aerospace. Traders are bullish on the results but debate why the share-price reaction has been muted.

GE Aerospace is an American aircraft company, which engages in the provision of jet and turboprop engines, as well as integrated systems for commercial, military, business, and general aviation aircraft. The firm's portfolio of brands includes Avio Aero, Unison, GE Additive, and Dowty Propellers. It operates through the following segments: Commercial Engines and Services, Defense and Propulsion Technologies, and Corporate and Other. The Commercial Engines and Services segment is involved in the design, development, manufacturing, and servicing of jet engines for commercial airframes, as well as business aviation and aeroderivative applications. The Defense and Propulsion Technologies segment offers defense engines and critical aircraft systems. The Corporate and Other segment relates to corporate functions and operations costs. The company was founded by Thomas Alva Edison in 1878 and is headquartered in Evendale, OH.

GE Aerospace

GEs quarterly results beat expectations and management raised its outlook, but shares fell as traders focused on rising costs, weaker free cash flow, and a loss in its insurance business. The reaction reflects a debate between strong aerospace demand and order growth versus pressure on margins and cash generation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

CMPS, MDGL, DFTX, GHRS, HELP Stocks In Spotlight Today – Why Wells Fargo Thinks Next Wave Of Depression Drugs Could Create New Winners

Equity

Wells Fargo began coverage on five biotech stocks on Monday, with only Compass Pathways receiving an ‘Equal-Weight’ rating while the rest received ‘Overweight’ ratings.


A Depression Drug Just Cleared a Key Hurdle Early, and the Market for New Mental Health Treatments Keeps Widening

A Depression Drug Just Cleared a Key Hurdle Early, and the Market for New Mental Health Treatments Keeps Widening A Depression Drug Just Cleared a Key Hurdle Early, and the Market for New Mental Health Treatments Keeps Widening PR Newswire NEW YORK and TORONTO, July 21, 2026 Issued on behalf of...

ATAI Stock Downgraded Across Wall Street – Why Analysts Believe Buyout By Eli Lilly Capped Near-Term Upside

H.C. Wainwright and Berenberg became the latest firms to downgrade the stock following Eli Lilly's acquisition agreement.


Futures Slide After Another Korea Rout, TSMA Results Revive AI Fears

Futures Slide After Another Korea Rout, TSMA Results Revive AI Fears

 Futures are lower, erasing much of yesterday's gain with both Nasdaq and Rusell lagging SPX, following a continued rollercoaster in Korea where stocks tumbled after the BOK hired rates for the first time in 3 years...

Is AtaiBeckley Stock Worth Buying After Its Stronger Rally in 2026?

ATAI's 2026 rally has raised expectations as key pipeline milestones approach, leaving the stock's outlook increasingly tied to clinical execution and upcoming data.

AtaiBeckley Reflects a New Push for Rapid-Acting Mental Health Drugs

ATAI is pursuing rapid-acting mental health treatments with key late-stage catalysts ahead, but its outlook still hinges on clinical execution and pipeline progress.

AtaiBeckley Stock Outlook Depends on Key Pipeline Catalysts in 2026

ATAI enters a catalyst-heavy 2026 as BPL-003 advances toward phase III, with upcoming pipeline milestones set to shape the clinical-stage biotech's outlook.

Multi-Billion-Dollar Battle for the Future of Depression Treatment Has Begun Creating a Huge Opportunity

Next-generation MDD drugs are driving a new era of innovation, investment, and commercial opportunity   New York, NY – June 30, 2026 – Market News Updates News Commentary – The way Major Depressive Disorder (MDD) is treated is changing faster than it has in years. For decades, most patients relied on traditional antidepressants that often […]
The post Multi-Billion-Dollar Battle for the Future of Depression Treatment Has Begun Creating a Huge Opportunity appeared first on Financial News Media.

A Breakthrough-Designated Depression Drug Is 86% Through Its Phase 3, With Topline Data Due This Year

A Breakthrough-Designated Depression Drug Is 86% Through Its Phase 3, With Topline Data Due This Year A Breakthrough-Designated Depression Drug Is 86% Through Its Phase 3, With Topline Data Due This Year PR Newswire NEW YORK and TORONTO, June 26, 2026 Issued on behalf of Helus PharmaHelus Pharma...

GH Research PLC (NASDAQ:GHRS) Given Average Recommendation of "Moderate Buy" by Brokerages

GH Research PLC (NASDAQ:GHRS - Get Free Report) has received an average recommendation of 'Moderate Buy' from the eleven research firms that are covering the firm, Marketbeat Ratings reports. One...

GH Research Plc is a holding company, which engages in the provision of biopharmaceutical products and services. It develops therapeutic products for patients with psychiatric and neurological disorders. The firm develops novel and proprietary 5-Methoxy-N and N-Dimethyltryptamine, or 5-MeO-DMT, therapies. The company was founded by Theis Terwey, Florian Schönharting, and Magnus Halle in 2018 and is headquartered in Dublin, Ireland.

GH Research PLC

Bearish Sentiment

<ul class="summary-bullets"><li>Wells Fargo said competition down the line could limit the long-term commercial potential of its therapy for treatment-resistant depression.</li><li>The firm initiated Helus Pharma with an ‘Overweight’ rating and a $16 price target, a near 100% upside potential from current levels.</li><li>Wells Fargo forecasts more than $7 billion in peak sales for Madrigal Pharmaceuticals’ Rezdiffra.</li></ul>Wells Fargo initiated coverage on five biotechnology companies, expressing optimism on several late-stage drug developers focused on depression therapies, including Helus Pharma (HELP), GH Research (GHRS), and Definium Therapeutics (DFTX), while taking a more cautious stance on Compass Pathways (CMPS).<h2 class="st-heading-2">Compass Could Face Competitive Challenges</h2>According to The Fly, Wells Fargo initiated Compass Pathways with an ‘Equal Weight’ rating and a $13 price target, implying a 12% upside potential from current levels.&nbsp;<a href="https://stocktwits.com/symbol/CMPS">CMPS stock</a> was up 2.6% at the time of writing.Analyst Benjamin Burnett said the company’s COMP360 therapy for treatment-resistant depression is likely to meet the U.S. Food and Drug Administration’s (FDA) approval standard after two positive Phase 3 studies. The latest trial, reported in February 2026, showed that two 25 mg doses of COMP360 delivered a statistically significant and clinically meaningful reduction in depression symptom severity, measured by the Montgomery–Åsberg Depression Rating Scale (MADRS), compared with the 1 mg dose.However, he noted that the treatment’s efficacy appears comparable to Johnson &amp; Johnson’s Spravato, while competition from follow-on therapies could limit its long-term commercial opportunity.Retail sentiment for CMPS on Stocktwits turned ‘bearish’ from ‘neutral’ a day earlier. The stock has seen strong buying interest so far this year, gaining more than 76%.<h2 class="st-heading-2">HELP Stock Has Attractive Risk/Reward Profile Ahead Of Phase 3 Results</h2>Wells Fargo initiated Helus Pharma with an ‘Overweight’ rating and a $16 price target, a near 100% upside potential from current levels.The firm thinks COMP360 data provide validation for Helus’ HLP003 in treatment-resistant depression.&nbsp;<a href="https://stocktwits.com/symbol/HELP">HELP stock</a> was up around 5% at the time of writing.Last week, Helus Pharma completed enrollment in its Phase 3 Approach Trial evaluating HLP003 in adults with moderate to severe major depressive disorder who have not responded adequately to antidepressants. The company expects to report Phase 3 results in the fourth quarter.The firm sees an attractive risk-reward profile for the shares ahead of the topline results.Retail sentiment on Stocktwits turned ‘extremely bullish’ from ‘bullish’ a day earlier, amid ‘extremely high’ message volumes. The stock has shed roughly 3% so far this year.<h2 class="st-heading-2">Wells Fargo Is Bullish On GH Research Despite Investor Skepticism</h2>The firm started GH Research with an ‘Overweight’ rating and a $44 price target, implying a 56% upside potential from its current levels.&nbsp;<a href="https://stocktwits.com/symbol/GHRS">GHRS stock</a> is up around 3.2%.In June, the company reported results of a Phase 2a trial for postpartum depression. The treatment met its primary endpoint, reducing depression scores by an average of 35.4 points by Day 8. The treatment was well tolerated, with no serious adverse events or treatment-related suicidal thoughts or behavior.Despite an over 12% increase in the stock price since then, Wells Fargo said the current valuation suggests investors remain unconvinced that the company’s encouraging Phase 2b depression data will be replicated in Phase 3 trials.The stock has gained more than 112% so far this year, while its retail sentiment on Stocktwits turned ‘neutral’ from ‘bullish’ a day earlier.<h2 class="st-heading-2">Definium Therapeutics Is Riding The Psychiatry Trend</h2>Wells Fargo also started coverage of Definium Therapeutics with an ‘Overweight’ rating and a $68 price target, indicating a 51% upside potential. The stock is currently up around 4%.The firm believes Spravato has validated the interventional psychiatry model for treating depression, creating room for new therapies.Definium’s lead candidate, DT120, met the primary endpoint in its Phase 3 Emerge trial in adults with major depressive disorder. Patients treated with DT120 saw a 13.3-point reduction in depression scores at six weeks, compared with a 5.2-point reduction in the placebo group. Wells Fargo believes the company is well positioned to benefit from growing demand for innovative mental health treatments.<a href="https://stocktwits.com/symbol/DFTX">DFTX shares</a> have gained more than 240% so far this year, while retail sentiment on Stocktwits has remained in the ‘bearish’ territory over the past 24 hours.<h2 class="st-heading-2">Madrigal’s Rezdiffra Has A Multi-billion-Dollar Sales Potential</h2>The firm launched coverage of Madrigal Pharmaceuticals with an ‘Overweight’ rating and a $685 price target, representing a 22% upside potential, while its stock is currently up around 3%.Wells Fargo forecasts more than $7 billion in peak sales for Rezdiffra, its lead medication to treat noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver fibrosis.The firm also added that physician surveys indicate concerns about GLP-1 drugs and competitive pressures are overstated, supporting durable growth in what it expects to be a ‘multi-drug market.’Retail sentiment surrounding&nbsp;<a href="https://stocktwits.com/symbol/MDGL">MDGL</a> turned ‘bullish’ from ‘neutral’ a day earlier. The stock is down around 6% so far this year.Also read:<a href="https://stocktwits.com/news-articles/markets/equity/capr-stock-is-crashing-today-fda-briefing-casts-doubt-on-duchenne-cell-therapy-before-key-vote/cZZx1IOR76P">&nbsp;CAPR Stock Is Crashing Today – FDA Briefing Casts Doubt On Duchenne Cell Therapy Before Key Vote</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

While Johnson & Johnson’s stock (JNJ) has risen 25.6% so far in 2025, Roche’s U.S.-listed stock (RHHBY) has gained 20% over the same period. (Photo credit: Getty Images)

Wells Fargo began coverage on five biotech stocks on Monday, with only Compass Pathways receiving an ‘Equal-Weight’ rating while the rest received ‘Overweight’ ratings.

Definium Therapeutics Inc.

Helus Pharma Inc.

Madrigal Pharmaceuticals Inc

Tema Neuroscience & Mental Health ETF

AdvisorShares Psychedelics ETF

$SPCX

$NFLX

$TSLA

$META

Which earnings release are you most looking forward to this week: $SPCX, $NFLX, $TSLA, or $META? Drop a comment for others.

Feed

News

Sentiment

Earnings

Fundamentals

Info

GHRS GH Research PLC

Fundamentals

Latest GHRS News